S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Gastric Cancer

Drug Information

Target Indication

Gastric Cancer

Clinical Trial

Last updated: 3/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Influenza (Healthy Volunteers)

Type 2 Diabetes Mellitus

Diphtheria

Non Small Cell Lung Cancer

Influenza